Preclinical studies proved that blocking the CXCR4/CXCL12 axis with plerixafor (AMD3100), CXCR4-specific peptides, or monoclonal antibodies reduced cancer growth and metastasis while promoting sensitization to chemotherapy, radiation, or immunotherapy [2,3,7,8,9,10,11]. Here, CXCL12 is linked to cancer.